⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12590 | 0.75 | — | — | |
| SCHEMBL13574813 | 0.75 | — | — | |
| SCHEMBL10180928 | 0.75 | — | — | |
| SCHEMBL7264424 | 0.73 | — | — | |
| SCHEMBL7264422 | 0.73 | — | — | |
| Ammonia Solution, Strong SCHEMBL20721963 | 0.72 | — | — | |
| SCHEMBL8830285 | 0.69 | — | — | |
| SCHEMBL4561668 | 0.65 | — | — | |
| SCHEMBL9963209 | 0.63 | — | — | |
| SCHEMBL10197115 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028603-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| EP-3116851-B1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INST FOR BIOLOGICAL STUDI (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-2414328-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| EP-3815689-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | National University Corporation Hokkaido University (JP) | 2021-05-05 | — | — | EP | disclosed |
| WO-2021069927-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-15 | — | — | WO | disclosed |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2019-11-12 | — | — | US | disclosed |
| EP-2922821-B1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10301268-B2 | Analogs of fexaramine and methods of making and using | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-05-28 | — | — | US | disclosed |
| US-10273247-B2 | Imidazothiazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2019-04-30 | — | — | US | disclosed |
| EP-3135114-B1 | DIARYL-AZOLE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2019-03-20 | — | — | EP | disclosed |
| WO-2007141502-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141517-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007071966-A1 | PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-7109228-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |